- Prof. Matsumura of Tokyo Medical University Presents Investigator-Initiated Pilot Study at EWMA 2026
- Average wound closure in 4.2 weeks; zero recurrence or reoperation during average 1.6-year follow-up
- SCAR-Q scar satisfaction scores of 265–300 out of 300; four patients achieving perfect scores
- U.S. and European clinicians highlight potential of OR-based regenerative platform

Photo: Prof. Hajime Matsumura of the Department of Plastic and Reconstructive Surgery, Tokyo Medical University, presenting study results

ROKIT Healthcare (KOSDAQ: 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, announced that Prof. Hajime Matsumura of the Department of Plastic and Reconstructive Surgery at Tokyo Medical University presented results from a Dr. INVIVO-based 3D bioprinting AMHAT application study at the European Wound Management Association conference (EWMA 2026) on May 7 (local time).

The study enrolled patients with non-melanoma skin cancer for whom primary closure following tumor resection was difficult or inappropriate. Participants had a mean age of 73.6 years, and the technology was applied in anatomically sensitive areas where aesthetic outcomes are critical, including the face and nose.

Average Wound Closure in 4.2 Weeks — No Recurrence or Reoperation Reported in Long-Term Follow-Up

According to Prof. Matsumura's presentation, complete wound closure was achieved in an average of 4.2 weeks. The mean residual wound area decreased progressively: 52% at week 1, 27% at week 2, 13% at week 3, 3% at week 4, and 0% at week 5.

Notably, no cases of skin cancer recurrence or reoperation were reported during a follow-up period averaging 1.6 years, with a maximum of 2 years.

Scar satisfaction outcomes were also positive. SCAR-Q — a patient-reported measure assessing the appearance, symptoms, and psychosocial impact of scars — yielded scores of 265 to 300 out of a possible 300, with four patients achieving a perfect score.

Prof. Matsumura stated, "This study is significant in that it demonstrated both rapid wound closure and high scar satisfaction in defect sites following skin cancer resection." He added, "Particularly encouraging results were observed in cosmetically sensitive areas such as the face, nose, cheeks, and forehead."

He further noted, "The absence of skin cancer recurrence or reoperation throughout an average follow-up of 1.6 years is also a notable finding," and described the Dr. INVIVO-based AMHAT approach as "a technique with promising potential for further investigation in post-resection skin cancer reconstruction."

Global Clinicians Highlight Potential of OR-Based Regenerative Platform

At EWMA 2026, ROKIT Healthcare conducted interviews with leading clinicians and researchers from the United States and Europe to explore potential applications of its regenerative medicine platform. Discussions covered skin regeneration, diabetic foot, tissue engineering, and vascular regeneration with specialists from Boston University School of Medicine and Boston Medical Center (BMC), the Max Planck Institute in Germany, and Pius Hospital in Germany.

Dr. Vitaly Volansky of the Wound Care Center at Boston Medical Center highlighted as a key differentiator the platform's ability to "reconstruct patient-derived extracellular matrix (ECM) into a 3D scaffold directly in the operating room, without chemical cell culture." He noted that this approach sets it apart from conventional tissue engineering methods and called for further clinical studies across diverse patient populations and indications to evaluate its therapeutic potential.

European researchers also expressed strong interest in the platform's minimally manipulated, OR-applicable approach. Dr. Mohammad Raufi, senior researcher at the Max Planck Institute, remarked that bypassing cell culture warrants consideration from both regulatory and clinical application perspectives. Dr. Lilia Burdik, a vascular surgeon at Pius Hospital, expressed interest in the platform's potential for expanding into vascular regeneration and blood flow improvement in diabetic foot treatment, and requested ongoing dialogue with the company.

A ROKIT Healthcare spokesperson commented, "This presentation is meaningful in that it introduced the potential of skin cancer regeneration technology through an investigator-initiated pilot study." The spokesperson added, "We will continue to explore clinical applications across a range of indications — including skin reconstruction, chronic wounds, and diabetic foot — through collaboration with global medical professionals."